AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION;아주대학교산학협력단
发明人:
KIM, Yong Sung,김용성,KIM, Ye Jin,김예진
申请号：
KRKR2017/003365
公开号：
WO2017/171373A3
申请日:
2017.03.28
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to methods for controlling resistance or sensitivity to an epidermal growth factor receptor (EFGR)-targeting agent through a peptide binding specifically to Neuropilin 1. In addition, the present invention relates to a composition for controlling resistance or sensitivity to an EGFR-targeting agent by co-administering a fusion antibody in which a peptide binding specifically to Neuropilin 1 is fused to an EGFR-targeting antibody, and a constant region of the heavy chain in an antibody in which the EGFR-targeting agent is fused to the peptide. Further, the fusion antibody in which a peptide binding specifically to Neuropilin 1 is fused to an EGFR-targeting antibody in accordance with the present invention allows for overcoming resistance to EGFR-targeting antibodies in pancreatic cancer. Furthermore, the fusion antibody in which a peptide binding specifically to Neuropilin 1 is fused to an EGFR-targeting antibody allows for overcoming resistance to EGFR-targeting antibodies even in the lung cancer that is resistant to EGFR-targeting antibodies. Hence, the peptide binding specifically to Neuropilin 1 in accordance with the present invention is expected to have high effects of treating various tumors resistant to EGFR-targeting agents.La présente invention concerne des procédés de régulation de la résistance ou de la sensibilité à un agent ciblant le récepteur du facteur de croissance épidermique (EFGR) par l'intermédiaire d'un peptide se liant spécifiquement à la neuropiline 1. De plus, la présente invention concerne une composition pour réguler la résistance ou la sensibilité à un agent ciblant l'EGFR par co-administration d'un anticorps de fusion dans lequel un peptide se liant spécifiquement à la neuropiline 1 est fusionné à un anticorps ciblant l'EGFR, et une région constante de la chaîne lourde dans un anticorps dans lequel l'agent ciblant l'EGFR est fusionné au peptide. En outre, l'anticorps de fusion dans lequel un peptide se liant
